<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35234322</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1460-9592</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Paediatric anaesthesia</Title>
          <ISOAbbreviation>Paediatr Anaesth</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Consistency of remifentanil concentrations in propofol-Remifentanil infusions. A laboratory-based study.</ArticleTitle>
        <Pagination>
          <StartPage>727</StartPage>
          <EndPage>731</EndPage>
          <MedlinePgn>727-731</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/pan.14427</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">There is increasing interest in two-agent single-pump intravenous infusions for anesthesia and sedation in pediatric patients. Propofol-remifentanil is one such mixture. The poor miscibility of such admixtures when remifentanil is added in very high concentrations and when the admixtures are maintained in static conditions has been demonstrated; however, these physiochemical properties have not been examined in clinically relevant concentrations or settings.</AbstractText>
          <AbstractText Label="AIM">To examine if propofol-remifentanil admixtures maintain consistent remifentanil delivery when mixed in clinically relevant remifentanil concentrations and subjected to the physical effects of an actively infusing, directly-engaged syringe driver system with an extension line, as occurs when propofol-remifentanil is administered to a patient.</AbstractText>
          <AbstractText Label="METHODS">A propofol 10 mg.ml<sup>-1</sup> combined with remifentanil 5 mcg.ml<sup>-1</sup> solution was run using a Paedfusor<sup>®</sup> propofol target-controlled infusion model for 10 kg and 20 kg children for 57 min at a target plasma concentration of 3 mcg.ml<sup>-1</sup> through a 30 ml syringe, 180 cm minimum volume extension line, lever lock cannula, interlink injection site, and 22 g intravenous cannula into sample pots. Samples were taken at the completion of the loading bolus, 1 and 2 min postcompletion of loading bolus, and every 5 min thereafter. The remifentanil concentration in these samples was then assayed using chromatography.</AbstractText>
          <AbstractText Label="RESULTS">There was no difference in the concentration of remifentanil in the samples based on the duration of infusion to the endpoint of 1 h, or on the patient weight model used. The concentration remained 5 mcg.ml<sup>-1</sup> +/- 0.5 mcg.ml<sup>-1</sup> per sample. The measurement uncertainty for the assay at 0.5 mcg.ml<sup>-1</sup> is +/- 0.2 mcg.ml<sup>-1</sup> .</AbstractText>
          <AbstractText Label="CONCLUSION">The concentration of remifentanil was 5 mcg.ml<sup>-1</sup> +/- 0.5 mcg.ml<sup>-1</sup> and was consistent across 57 min of infusion, and two different pediatric weight profiles.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wylie</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-3367-2447</Identifier>
            <AffiliationInfo>
              <Affiliation>Women's and Children's Hospital, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beale</LastName>
            <ForeName>Lee</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Women's and Children's Hospital, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Westley</LastName>
            <ForeName>Ian</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology, Chemical Pathology, SA Pathology, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Biomedical Sciences, UniSA, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Paediatr Anaesth</MedlineTA>
        <NlmUniqueID>9206575</NlmUniqueID>
        <ISSNLinking>1155-5645</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P10582JYYK</RegistryNumber>
          <NameOfSubstance UI="D000077208">Remifentanil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YI7VU623SF</RegistryNumber>
          <NameOfSubstance UI="D015742">Propofol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000758" MajorTopicYN="Y">Anesthesia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000771" MajorTopicYN="N">Anesthesia, Intravenous</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015742" MajorTopicYN="Y">Propofol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077208" MajorTopicYN="N">Remifentanil</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">TIVA</Keyword>
        <Keyword MajorTopicYN="Y">pediatric TIVA</Keyword>
        <Keyword MajorTopicYN="Y">propofol admixtures</Keyword>
        <Keyword MajorTopicYN="Y">propofol total intravenous anesthesia</Keyword>
        <Keyword MajorTopicYN="Y">remifentanil</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>8</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35234322</ArticleId>
        <ArticleId IdType="doi">10.1111/pan.14427</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Baxter AG, McCormack J. TIVA in children an editorial. Pediatr Anesthes. 2019;29(9):890-891.</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson BJ, Bagshaw O. Practicalities of total intravenous anesthesia and target-controlled infusion in children. Anesthesiology. 2019;131(1):164-185.</Citation>
        </Reference>
        <Reference>
          <Citation>Lauder GR. Total intravenous anaesthesia will supercede inhalational anesthesia in pediatric anesthetic practice. Pediatr Anesthes. 2015;25(1):52-64.</Citation>
        </Reference>
        <Reference>
          <Citation>Lauder GR, Thomas M, von Ungern-Sternberg BS, Engelhardt T. Volatiles or TIVA: which is the standard of care for pediatric airway procedures? A pro-Con discussion. Pediatr Anesthes. 2020;30(3):209-220.</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson BJ, Houghton J. Ankle biters: how to use TIVA in children. In: Irwin M, Wong G, Lam S, eds. editorsTaking on TIVA: Debunking Myths and Dispelling Misunderstandings. Cambridge University Publishing; 2019:111-123.</Citation>
        </Reference>
        <Reference>
          <Citation>Goh AC, Bagshaw O, Courtman S. A follow-up survey of total intravenous anesthesia usage in children in the UKand Ireland. Pediatr Anesthes. 2019;29(2):180-185.</Citation>
        </Reference>
        <Reference>
          <Citation>Hill M, Peat W, Courtman S. A national survey of propofol infusion use by paediatric anaesthetists in Great Britain and Ireland. Pediatr Anesthes. 2008;18(6):488-493.</Citation>
        </Reference>
        <Reference>
          <Citation>Kramer KJ, Ganzberg S, Prior S, Rashid RG. Comparison of propofol-remifentanil versus propofol-ketamine deep sedation for third molar surgery. Anesth Prog. 2012;59(3):107-117.</Citation>
        </Reference>
        <Reference>
          <Citation>Berkenbosch JW, Graff GR, Stark JM, Ner Z, Tobias JD. Use of a remifentanil-propofol mixture for pediatric flexible fibreoptic bronchoscopy sedation. Pediatr Anesthes. 2004;14(11):941-946.</Citation>
        </Reference>
        <Reference>
          <Citation>Absalom AR, Rigby-Jones AE, Rushton AR, Sneyd JR. Demistifying the ‘Mixifusor’. Pediatr Anesthes. 2020;30(12):1292-1298.</Citation>
        </Reference>
        <Reference>
          <Citation>Stewart JT, Warren FW, Maddox FC, Viswanathan K, Fox JL. The stability of remifentanil hydrochloride and propofol mixtures in polypropylene syringes and polyvinylchloride bags at 22C - 24C. Anesth Analg. 2000;90(6):1450-1451.</Citation>
        </Reference>
        <Reference>
          <Citation>O'Connor S, Zhang YL, Christians U, Morrison JE, Friesen RH. Remifentanil and propofol undergo separation and layering when mixed in the same syringe for total intravenous anesthesia. Pediatr Anesthes. 2016;26(7):703-709.</Citation>
        </Reference>
        <Reference>
          <Citation>Bagshaw O, McCormack J, Brooks P, Marriott D, Baxter A. The safety profile and effectiveness of propofol-remifentanil mixtures for total intravenous anaesthesia in children. Pediatr Anesthes. 2020;30(12):1331-1339.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Orgainsation Child growth standards. Weight for age charts. https://www.who.int/tools/child-growth-standards/standards/weight-for-age</Citation>
        </Reference>
        <Reference>
          <Citation>Bartels DD, McCann ME, Davidson AJ, et al. Estimating pediatric general anesthesia exposure: quantifying duration and risk. Pediatr Anesthes. 2018;28(6):520-527.</Citation>
        </Reference>
        <Reference>
          <Citation>Mani V, Morton NS. Overview of total intravenous anesthesia in children. Pediatr Anesthes. 2010;20(3):211-222.</Citation>
        </Reference>
        <Reference>
          <Citation>Absalom A, Amutike D, Lal A, White M, Kenny GN. Accuracy of the ‘Paedfusor’ in children undergoing cardiac surgery or catheterization. Br J Anaesth. 2003;91(4):507-513.</Citation>
        </Reference>
        <Reference>
          <Citation>Sui BC, Wagner A, Usher AG, Cave DA, Tang C. Combined propofol and remifentanil intravenous anesthesia for pediatric patients undergoing magnetic resonance imaging. Pediatr Anesthes. 2005;15(5):397-401.</Citation>
        </Reference>
        <Reference>
          <Citation>Enforcement Policy for Infusion Pumps and Accessories During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry and Food And Drug Administration Staff 2020. Food and Drug Administration Centre for Devices and Radiological Health. https://www.fda.gov/emergency-preparedness-and-response/mom-issues/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders. Accessed April 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Nemec K, Germ E, Shulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. Pharmazie. 2009;64(2):94-97.</Citation>
        </Reference>
        <Reference>
          <Citation>Bagshaw O. Editorial - propofol and remifentanil: to mix or not to mix. Pediatr Anesthes. 2016;26(7):677-679.</Citation>
        </Reference>
        <Reference>
          <Citation>Shearn J, Directly engaged syringe driver system. United States Patent Office. Alaris Medical Systems Inc.; 2003:6.</Citation>
        </Reference>
        <Reference>
          <Citation>Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - two new Methods of evaluating IV emulsion compatibility. Ann Pharmacother. 1996;30(3):228-232.</Citation>
        </Reference>
        <Reference>
          <Citation>Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. Eur Jl of Hosp Pharm. 2017;24(5):293-303.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35234322</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1460-9592</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Paediatric anaesthesia</Title>
          <ISOAbbreviation>Paediatr Anaesth</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Consistency of remifentanil concentrations in propofol-Remifentanil infusions. A laboratory-based study.</ArticleTitle>
        <Pagination>
          <StartPage>727</StartPage>
          <EndPage>731</EndPage>
          <MedlinePgn>727-731</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/pan.14427</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">There is increasing interest in two-agent single-pump intravenous infusions for anesthesia and sedation in pediatric patients. Propofol-remifentanil is one such mixture. The poor miscibility of such admixtures when remifentanil is added in very high concentrations and when the admixtures are maintained in static conditions has been demonstrated; however, these physiochemical properties have not been examined in clinically relevant concentrations or settings.</AbstractText>
          <AbstractText Label="AIM">To examine if propofol-remifentanil admixtures maintain consistent remifentanil delivery when mixed in clinically relevant remifentanil concentrations and subjected to the physical effects of an actively infusing, directly-engaged syringe driver system with an extension line, as occurs when propofol-remifentanil is administered to a patient.</AbstractText>
          <AbstractText Label="METHODS">A propofol 10 mg.ml<sup>-1</sup> combined with remifentanil 5 mcg.ml<sup>-1</sup> solution was run using a Paedfusor<sup>®</sup> propofol target-controlled infusion model for 10 kg and 20 kg children for 57 min at a target plasma concentration of 3 mcg.ml<sup>-1</sup> through a 30 ml syringe, 180 cm minimum volume extension line, lever lock cannula, interlink injection site, and 22 g intravenous cannula into sample pots. Samples were taken at the completion of the loading bolus, 1 and 2 min postcompletion of loading bolus, and every 5 min thereafter. The remifentanil concentration in these samples was then assayed using chromatography.</AbstractText>
          <AbstractText Label="RESULTS">There was no difference in the concentration of remifentanil in the samples based on the duration of infusion to the endpoint of 1 h, or on the patient weight model used. The concentration remained 5 mcg.ml<sup>-1</sup> +/- 0.5 mcg.ml<sup>-1</sup> per sample. The measurement uncertainty for the assay at 0.5 mcg.ml<sup>-1</sup> is +/- 0.2 mcg.ml<sup>-1</sup> .</AbstractText>
          <AbstractText Label="CONCLUSION">The concentration of remifentanil was 5 mcg.ml<sup>-1</sup> +/- 0.5 mcg.ml<sup>-1</sup> and was consistent across 57 min of infusion, and two different pediatric weight profiles.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wylie</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-3367-2447</Identifier>
            <AffiliationInfo>
              <Affiliation>Women's and Children's Hospital, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beale</LastName>
            <ForeName>Lee</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Women's and Children's Hospital, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Westley</LastName>
            <ForeName>Ian</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology, Chemical Pathology, SA Pathology, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Biomedical Sciences, UniSA, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Paediatr Anaesth</MedlineTA>
        <NlmUniqueID>9206575</NlmUniqueID>
        <ISSNLinking>1155-5645</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P10582JYYK</RegistryNumber>
          <NameOfSubstance UI="D000077208">Remifentanil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YI7VU623SF</RegistryNumber>
          <NameOfSubstance UI="D015742">Propofol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000758" MajorTopicYN="Y">Anesthesia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000771" MajorTopicYN="N">Anesthesia, Intravenous</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015742" MajorTopicYN="Y">Propofol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077208" MajorTopicYN="N">Remifentanil</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">TIVA</Keyword>
        <Keyword MajorTopicYN="Y">pediatric TIVA</Keyword>
        <Keyword MajorTopicYN="Y">propofol admixtures</Keyword>
        <Keyword MajorTopicYN="Y">propofol total intravenous anesthesia</Keyword>
        <Keyword MajorTopicYN="Y">remifentanil</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>8</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35234322</ArticleId>
        <ArticleId IdType="doi">10.1111/pan.14427</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Baxter AG, McCormack J. TIVA in children an editorial. Pediatr Anesthes. 2019;29(9):890-891.</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson BJ, Bagshaw O. Practicalities of total intravenous anesthesia and target-controlled infusion in children. Anesthesiology. 2019;131(1):164-185.</Citation>
        </Reference>
        <Reference>
          <Citation>Lauder GR. Total intravenous anaesthesia will supercede inhalational anesthesia in pediatric anesthetic practice. Pediatr Anesthes. 2015;25(1):52-64.</Citation>
        </Reference>
        <Reference>
          <Citation>Lauder GR, Thomas M, von Ungern-Sternberg BS, Engelhardt T. Volatiles or TIVA: which is the standard of care for pediatric airway procedures? A pro-Con discussion. Pediatr Anesthes. 2020;30(3):209-220.</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson BJ, Houghton J. Ankle biters: how to use TIVA in children. In: Irwin M, Wong G, Lam S, eds. editorsTaking on TIVA: Debunking Myths and Dispelling Misunderstandings. Cambridge University Publishing; 2019:111-123.</Citation>
        </Reference>
        <Reference>
          <Citation>Goh AC, Bagshaw O, Courtman S. A follow-up survey of total intravenous anesthesia usage in children in the UKand Ireland. Pediatr Anesthes. 2019;29(2):180-185.</Citation>
        </Reference>
        <Reference>
          <Citation>Hill M, Peat W, Courtman S. A national survey of propofol infusion use by paediatric anaesthetists in Great Britain and Ireland. Pediatr Anesthes. 2008;18(6):488-493.</Citation>
        </Reference>
        <Reference>
          <Citation>Kramer KJ, Ganzberg S, Prior S, Rashid RG. Comparison of propofol-remifentanil versus propofol-ketamine deep sedation for third molar surgery. Anesth Prog. 2012;59(3):107-117.</Citation>
        </Reference>
        <Reference>
          <Citation>Berkenbosch JW, Graff GR, Stark JM, Ner Z, Tobias JD. Use of a remifentanil-propofol mixture for pediatric flexible fibreoptic bronchoscopy sedation. Pediatr Anesthes. 2004;14(11):941-946.</Citation>
        </Reference>
        <Reference>
          <Citation>Absalom AR, Rigby-Jones AE, Rushton AR, Sneyd JR. Demistifying the ‘Mixifusor’. Pediatr Anesthes. 2020;30(12):1292-1298.</Citation>
        </Reference>
        <Reference>
          <Citation>Stewart JT, Warren FW, Maddox FC, Viswanathan K, Fox JL. The stability of remifentanil hydrochloride and propofol mixtures in polypropylene syringes and polyvinylchloride bags at 22C - 24C. Anesth Analg. 2000;90(6):1450-1451.</Citation>
        </Reference>
        <Reference>
          <Citation>O'Connor S, Zhang YL, Christians U, Morrison JE, Friesen RH. Remifentanil and propofol undergo separation and layering when mixed in the same syringe for total intravenous anesthesia. Pediatr Anesthes. 2016;26(7):703-709.</Citation>
        </Reference>
        <Reference>
          <Citation>Bagshaw O, McCormack J, Brooks P, Marriott D, Baxter A. The safety profile and effectiveness of propofol-remifentanil mixtures for total intravenous anaesthesia in children. Pediatr Anesthes. 2020;30(12):1331-1339.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Orgainsation Child growth standards. Weight for age charts. https://www.who.int/tools/child-growth-standards/standards/weight-for-age</Citation>
        </Reference>
        <Reference>
          <Citation>Bartels DD, McCann ME, Davidson AJ, et al. Estimating pediatric general anesthesia exposure: quantifying duration and risk. Pediatr Anesthes. 2018;28(6):520-527.</Citation>
        </Reference>
        <Reference>
          <Citation>Mani V, Morton NS. Overview of total intravenous anesthesia in children. Pediatr Anesthes. 2010;20(3):211-222.</Citation>
        </Reference>
        <Reference>
          <Citation>Absalom A, Amutike D, Lal A, White M, Kenny GN. Accuracy of the ‘Paedfusor’ in children undergoing cardiac surgery or catheterization. Br J Anaesth. 2003;91(4):507-513.</Citation>
        </Reference>
        <Reference>
          <Citation>Sui BC, Wagner A, Usher AG, Cave DA, Tang C. Combined propofol and remifentanil intravenous anesthesia for pediatric patients undergoing magnetic resonance imaging. Pediatr Anesthes. 2005;15(5):397-401.</Citation>
        </Reference>
        <Reference>
          <Citation>Enforcement Policy for Infusion Pumps and Accessories During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry and Food And Drug Administration Staff 2020. Food and Drug Administration Centre for Devices and Radiological Health. https://www.fda.gov/emergency-preparedness-and-response/mom-issues/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders. Accessed April 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Nemec K, Germ E, Shulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. Pharmazie. 2009;64(2):94-97.</Citation>
        </Reference>
        <Reference>
          <Citation>Bagshaw O. Editorial - propofol and remifentanil: to mix or not to mix. Pediatr Anesthes. 2016;26(7):677-679.</Citation>
        </Reference>
        <Reference>
          <Citation>Shearn J, Directly engaged syringe driver system. United States Patent Office. Alaris Medical Systems Inc.; 2003:6.</Citation>
        </Reference>
        <Reference>
          <Citation>Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - two new Methods of evaluating IV emulsion compatibility. Ann Pharmacother. 1996;30(3):228-232.</Citation>
        </Reference>
        <Reference>
          <Citation>Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. Eur Jl of Hosp Pharm. 2017;24(5):293-303.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
